Jubilant Life Sciences, a prominent player in the pharmaceutical and life sciences sector, is headquartered in Noida, India. Founded in 1978, the company has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in contract manufacturing, active pharmaceutical ingredients (APIs), and drug delivery solutions, Jubilant Life Sciences is recognised for its commitment to quality and innovation. The company’s core offerings, which include a diverse range of generic pharmaceuticals and specialty chemicals, set it apart in a competitive market. With a focus on sustainability and advanced technology, Jubilant Life Sciences has achieved significant milestones, including multiple regulatory approvals and partnerships with leading global firms. This positions the company as a trusted partner in the healthcare industry, dedicated to improving patient outcomes worldwide.
How does Jubilant Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Jubilant Life Sciences's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Jubilant Life Sciences reported total carbon emissions of approximately 746,000,000 kg CO2e, comprising 8,620,000 kg CO2e from Scope 1, 68,152,000 kg CO2e from Scope 2, and 737,234,000 kg CO2e from Scope 3 emissions. This represents a slight increase in emissions compared to 2023, where total emissions were about 675,000,000 kg CO2e, with Scope 1 at 8,492,000 kg CO2e, Scope 2 at 54,703,000 kg CO2e, and Scope 3 at 662,296,000 kg CO2e. Jubilant Life Sciences has set ambitious climate commitments, aiming for net zero emissions by 2050 for both Scope 1 and Scope 2 emissions. This long-term target was established in 2023, reflecting the company's commitment to reducing its carbon footprint significantly over the coming decades. The company has disclosed emissions data across all three scopes, demonstrating transparency in its reporting. Notably, the emissions data is sourced from Jubilant Pharmova Limited, indicating a direct relationship in data reporting and sustainability initiatives. Overall, Jubilant Life Sciences is actively working towards its climate goals while managing a substantial carbon footprint, particularly in Scope 3 emissions, which remain the largest contributor to its total emissions profile.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 894,456,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 107,906,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 12,057,000 | - | - | - | 00,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jubilant Life Sciences has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
